Trial Profile
The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 01 Jul 2019
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- 01 Sep 2012 Results published in the Metabolism - Clinical and Experimental.
- 21 Apr 2010 Planned end date changed from 1 Jun 2009 to 1 May 2010 as reported by ClinicalTrials.gov.
- 21 Apr 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.